Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report

Christiaan F. Mooij1*, Rick Hermsen2, Esther P. A. H. Hoppenreij3, Chantal P. Bleeker-Rovers4, Marloes M. IJland1 and Lioe-Fee de Geus-Oei2

Abstract

Background: Henoch-Schönlein vasculitis is the most common systemic vasculitis in children. Arthritis or arthralgia occurs in 80% of patients. We believe this to be the first case report to describe the finding of polyarthritis in a fludeoxyglucose positron emission tomography-computed tomography scan in a patient with Henoch-Schönlein vasculitis without clinical signs of arthritis.

Case presentation: A 4.5-year-old Caucasian boy presented with fever of 4 days’ duration followed by debilitating migratory arthralgia and inflammation. He underwent a fludeoxyglucose positron emission tomography-computed tomography scan to exclude a possible malignant cause or to detect any infectious or autoimmune focus of his symptoms. Fludeoxyglucose uptake was observed in multiple large joints and in multiple tendons. These findings suggested active polyarthritis and polytendinitis. However, physical and ultrasound evaluations did not show any signs of arthritis in our patient, despite his evident arthralgia.

Conclusions: Fludeoxyglucose positron emission tomography-computed tomography might be able to detect inflammatory activity in painful joints that cannot yet be detected clinically or with ultrasound evaluation in a patient with Henoch-Schönlein vasculitis. Therefore, fludeoxyglucose positron emission tomography-computed tomography can be of additional value in the diagnostic workup of patients with an unresolved diagnosis of suspected autoimmune disease, especially in patients with unresolved arthralgia and fever of unknown cause.

Keywords: Henoch-Schönlein, FDG-PET/CT, polyarthritis

* Correspondence: christiaan.mooij@radboudumc.nl
1 Department of Pediatrics, Amalia Children’s Hospital, Radboud University Medical Centre, PO Box 91016500 HB Nijmegen, The Netherlands
Full list of author information is available at the end of the article

© 2016 Mooij et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Henoch-Schönlein purpura is the most common systemic vasculitis in children. Henoch-Schönlein purpura is a type of small vessel vasculitis. Validated classification criteria for Henoch-Schönlein purpura have been proposed by the European League Against Rheumatism (EULAR) and Pediatric Rheumatology European Society (PRES). A patient’s disease is classified as Henoch-Schönlein purpura in the presence of purpura or petechiae (mandatory) with lower limb predominance plus one of four criteria: (1) abdominal pain; (2) histopathology (IgA); (3) arthritis or arthralgia; or (4) renal involvement [1].

The incidence of Henoch-Schönlein purpura is reported to be 10–20 per 100,000 children [2–6]. Henoch-Schönlein purpura can be diagnosed at any age, but is most common in children between 2 and 6 years of age. The rash of Henoch-Schönlein purpura is considered a classical symptom; however, in 30–40 % of cases it is not the presenting symptom, and the purpura is preceded by abdominal pain or arthralgia. Although only 15–25 % of patients with Henoch-Schönlein purpura present with arthritis or arthralgia, over the course of the disease approximately 80 % of patients have joint involvement [7]. The reported prevalence of arthritis as a symptom of Henoch-Schönlein purpura in pediatric patients varies in the literature from 61 to 92 % [8–13]. Usually the large joints of the lower limbs are affected. Symptoms of joint involvement include pain, swelling, and decreased range of movement [7].

In this report, we present the case of a 4.5-year-old boy with a final diagnosis of Henoch-Schönlein purpura who did not have clinical signs of arthritis. A fludeoxyglucose (FDG) PET/CT scan, however, showed FDG uptake in multiple large joints and in multiple tendons. $^{18}$F-FDG is a glucose analog that reflects the energy demand of inflammatory and/or malignant cells. Therefore, an increased uptake of $^{18}$F-FDG results from the increased metabolism of either inflammatory or malignant cells. In our case, the findings suggested active polyarthritis and polytendinitis, suggesting that an FDG-PET/CT scan can show inflammatory activity in painful joints that cannot yet be detected clinically or with ultrasound evaluation.

Case presentation
A 4.5-year-old Caucasian boy without a previous medical history presented to the pediatric outpatient clinic of a local hospital with a fever of 40.1 °C without clear focal symptoms. He was reported as being less active. He refused to walk and reported mild myalgia, but did not complain about joint pain. His parents reported that he had had a painful throat 2–3 weeks prior to presentation. At that time, no doctor was consulted. Two weeks prior to presentation his parents noticed peeling of the skin on his fingers, which recurred 1 day prior to presentation. A timeline of this case is shown in Table 1.

| Time point | Event |
|------------|-------|
| Two week prior to presentation | Upper respiratory tract infection with a painful throat, no doctor was consulted |
| Day 1 - Presentation | Presentation to a local hospital with fever without clear focal symptoms |
| Day 1 - Presentation | Treatment with amoxicillin-clavulanic acid for a suspected bacterial lymphadenopathy |
| Day 4 | Patient was referred to the university hospital because of possible Kawasaki disease |
| Day 7 | Treatment with intravenous immunoglobulins for possible incomplete Kawasaki disease |
| Day 8 | Treatment with intravenous immunoglobulins for possible incomplete Kawasaki disease |
| Day 9 | Migrating joint pains in his neck, arms, and legs |
| Day 9 | No signs of arthritis on physical examination |
| Day 10 | Started treatment with diclofenac |
| Day 13 | FDG-PET/CT: increased FDG uptake in multiple joints (polyarthritis) and multiple bilateral cervical lymph nodes |
| Day 14 | Ultrasound evaluation of his joints: no signs of arthritis |
| Day 17 | Clinical improvement with diclofenac treatment |
| Day 24 | Discharged without establishing a diagnosis |
| Day 25 | Evaluation at our outpatient clinic |
| Day 25 | Multiple purpura on his lower limbs and buttocks for 1 day |
| Day 25 | Skin biopsy: leukocytoclastic vasculitis with positive IgA depositions |
| Day 25 | Diagnosis was established: Henoch-Schönlein vasculitis |
| Day 25 | Treatment with diclofenac was continued |
| Day 25 | Presentation with bloody stools and abdominal pain |
| Day 25 | Ultrasound: no signs of invagination or thickened intestinal walls |
| Day 25 | Treatment with prednisolone was started, diclofenac was discontinued |
| Day 35 | Clinical improvement |
| Day 35 | Dosage of prednisolone was lowered |
| Day 63 | Relapse in joint pain and abdominal pain |
| Day 63 | Renal manifestation of Henoch-Schönlein vasculitis: hematuria and proteinuria |
| Day 63 | Dosage of prednisolone was increased |
| Day 73 | No clinical signs of Henoch-Schönlein vasculitis |
| Day 73 | Treatment with prednisolone was discontinued after gradually lowering the dosage |

Table 1 A timeline of events for a 4.5-year-old boy with Henoch-Schönlein vasculitis

Our patient was vaccinated according to the Dutch National Immunization Program.

A physical examination at presentation revealed a left-sided torticollis and edema of both hands and feet. Our patient was irritable, without clinical sings of meningitis. The rest of his physical examination, including an inspection of his ears, nose, and throat, was normal. His vital signs were normal. An ultrasound evaluation demonstrated bilateral
enlarged cervical lymph nodes, not noted on palpation during the physical examination. Because lymphadenopathy of a bacterial origin was suspected, treatment was started with an intravenous course of amoxicillin-clavulanic acid and diclofenac. A blood test revealed an anti-streptolysin O titer of 7590 U/ml, suggestive of a prior streptococcal infection. Despite this treatment, his fever persisted. Owing to the combination of fever, edema of hands and feet, mild conjunctivitis, cervical lymphadenopathy, and irritable behavior, Kawasaki disease was considered and he was referred to our university hospital for further evaluation 3 days after presentation.

On cardiac ultrasound evaluation, no involvement of his coronary arteries was observed. A biochemical evaluation showed an increased erythrocyte sedimentation rate (127 mm/h) and low CRP (9 mg/l). Although our patient did not meet the diagnostic criteria for Kawasaki disease, given that his fever had only persisted for up to 4 days, he was treated twice with 2 g/kg body-weight of intravenous immunoglobulins (IVIG) for possible incomplete Kawasaki disease. Treatment with IVIG, however, did not result in clinical improvement. The enlargement of his cervical lymph nodes decreased over time as evaluated by ultrasonography.

Our patient then developed migrating joint pains in his neck, arms, and legs 8 days after presentation. Diclofenac, but not acetaminophen, was effective in treating these arthralgias. Diclofenac treatment (12.5 mg thrice daily) was started 9 days after presentation and his arthralgia resolved within 2 days of treatment. He also developed finger contractures: both active and passive straightening were affected. Furthermore,

| Laboratory test                          | Result         | Time of laboratory test |
|-----------------------------------------|----------------|-------------------------|
| Hemoglobin                              | 6.0 mmol/l     | Day 6                   |
| Leukocytes                              | 10.9 × 10⁹/l   | Day 6                   |
| Manual blood count                      | No abnormalities| Day 6                   |
| Alanine aminotransferase (ALAT)         | 29 U/l         | Day 6                   |
| Aspartate aminotransferase (ASAT)       | 42 U/l         | Day 6                   |
| Gamma-glutamyl transpeptidase           | 14 U/l         | Day 6                   |
| Lactate dehydrogenase (LDH)             | 370 U/l        | Day 6                   |
| Creatinine                              | 25 μmol/l      | Day 6                   |
| Urea                                    | 5.7 mmol/l     | Day 6                   |
| Ferritin                                | 100 μg/l       | Day 13                  |
| Anti-Nuclear Antibody (ANA)             | Weak positive  | Day 9                   |
| Anti-Neutrophil Cytoplasmic Antibody (ANCA) | Negative     | Day 9                   |
| IgG                                     | 28.80 g/l      | Day 7                   |
| Urine test                              | No proteinuria and no hematuria | Day 4, 9, 12, and 24 |
an antalgic gait was observed. He did not have any clinical signs of arthritis. During his hospital stay, our patient developed hypertension (highest blood pressure 130/93 mmHg; above the 90th percentile for sex and age). Because he did not improve clinically over time and no infectious cause could be identified, an autoimmune disease or a malignancy with paraneoplastic arthralgias was considered. Results of laboratory investigations are shown in Table 2. To exclude a possible malignant cause or to detect any infectious or autoimmune focus, an FDG-PET/CT scan was performed.

Increased FDG uptake was observed in multiple large joints, without profuse effusions on the low-dose CT (Fig. 1), and in multiple tendons, such as the tendons of the distal tibialis anterior and the ischiopubic ramus (Fig. 2). These findings suggested active polyarthritis and polytendinitis. Furthermore, the FDG-PET/CT showed multiple bilateral metabolically active cervical lymph nodes, probably due to a previous upper respiratory tract infection (Fig. 3). A diffuse, slightly increased FDG uptake in his spleen was observed, possibly in the context of an inflammatory response. A long, stretched FDG uptake in the medial part of his right lower leg was due to FDG stasis after intravenous injection at that site.

Subsequently, our patient was referred for ultrasound evaluation of all joints because of the discrepancy between the findings in the physical examination (no arthritis) and on the FDG-PET/CT (polyarthritis). This ultrasound examination (with power Doppler), however, did not show hydropses, synovitis, or other signs of arthritis in any joint. The dermatologist was involved during admission because our patient showed minimal petchiae in the popliteal area. No skin biopsy was performed at that time.

Treatment with diclofenac led to clinical improvement. Without establishing a diagnosis, our patient was...
discharged on diclofenac treatment thrice daily. Evaluation at our outpatient clinic the next week revealed the presence of multiple purpura on his lower limbs and buttocks. These skin lesions had been present for 1 day. A skin biopsy, taken from an area with active lesions on his lower leg, showed a leukocytoclastic vasculitis with positive IgA depositions, which confirmed the diagnosis of Henoch-Schönlein vasculitis.

The day after his visit to the outpatient clinic, our patient presented with bloody stools and abdominal pain. An abdominal ultrasound did not show any signs of invagination or thickened intestinal walls. His arthralgia and antalgic gait were still present. Owing to the severity of his clinical symptoms (pain and bloody stools), treatment with prednisolone was started and diclofenac was discontinued. Results of a urine evaluation at that time were normal. Our patient improved rapidly after starting prednisolone treatment; the dosage was therefore lowered 10 days later. After 15 days of treatment, our patient was free of symptoms. One month later a relapse in joint pain and abdominal pain occurred and he developed renal manifestations (hematuria and proteinuria). The dosage of the prednisolone was increased again. Finally, prednisolone treatment was stopped 2.5 months after starting, when our patient was completely free of symptoms.

Discussion
The presented case demonstrates that FDG-PET/CT can show signs of inflammation in joints and tendons without signs of arthritis on physical and ultrasound evaluation in a pediatric patient with Henoch-Schönlein vasculitis. Approximately 80 % of patients with Henoch-Schönlein vasculitis develop arthritis or arthralgia. The exact etiology of arthritis in Henoch-Schönlein vasculitis is unknown. A study on synovial histology in Behçet’s disease, another systemic vasculitis, showed inflammation and infiltration with lymphocytes and neutrophils and no local signs of vasculitis [14]. The hypothesis of infiltration with lymphocytes could explain the increased FDG uptake in FDG-PET/CT in the presented case, because these activated lymphocytes consume FDG. In some cases, patients present with arthritis or arthralgia in the absence of the typical skin lesions [2, 7]. The absence of skin lesions can impede establishment of the diagnosis, as was illustrated in our case. Hypothetically, the treatment with IVIG in our patient may have delayed the inflammatory cascade, consequently leading to the delayed presentation of skin lesions [15]. It is well known that systemic symptoms may precede purpura in patients with Henoch-Schönlein vasculitis. The only case published on FDG-PET/CT in an adult patient with Henoch-Schönlein vasculitis describes the presence of a lung abscess [16]. However, as far as we know, the finding that FDG-PET/CT can reveal metabolically active, otherwise undetectable arthritis in patients with Henoch-Schönlein vasculitis has not previously been published. We suggest that FDG-PET/CT can detect increased inflammatory activity in patients with arthralgia before the clinical signs of arthritis are present.

This case illustrates that FDG-PET/CT can provide clues in a challenging diagnostic workup of a patient with unresolved arthralgia and fever of unknown origin. The finding of multiple bilateral active cervical lymph nodes suggests a preceding upper respiratory tract infection, a known trigger for Henoch-Schönlein vasculitis. It is well known that FDG-PET/CT is a very sensitive diagnostic tool to detect inflammation, especially in patients with fever of unknown origin and in patients with active rheumatic diseases [17, 18]. Available data suggest that FDG-PET/CT is favorable to MRI and CT as a diagnostic tool in patients with fever of unknown origin [17]. Furthermore, FDG-PET/CT appears to be superior to ultrasound and MRI in the diagnosis of large vessel vasculitis [18]. Studies on the role of FDG-PET/CT in small vessel vasculitis, like Henoch-Schönlein vasculitis, are lacking [19–21]. A recent study in patients with granulomatosis with polyangiitis, another small vessel vasculitis, showed that FDG-PET/CT can detect occult sites of disease activity [22]. The presented case suggests that FDG-PET/CT is also capable of detecting synovitis as a systemic manifestation of Henoch-Schönlein vasculitis. More studies are needed to evaluate the clinical use of FDG-PET/CT in Henoch-Schönlein and other small vessel vasculitides.

A disadvantage of FDG-PET/CT in children is the use of ionizing radiation. Because children are more susceptible to ionizing radiation than adults, there is a preference to use imaging techniques that do not use ionizing radiation, such as ultrasound or MRI. In specific cases, however, these techniques are not able to point to the diagnosis. In such cases the use of FDG-PET/CT in children is justified and can be very helpful and necessary to visualize inflammatory processes or other diseases showing a high metabolism, such as neoplasms. It must be emphasized that the most recent PET scanners with novel detector technology are capable of detecting ultra-low tracer doses, making reductions in injected dose possible. The recent introduction of hybrid PET-MRI systems can further reduce radiation burden.

Conclusions
FDG-PET/CT might be able to detect subclinical synovitis in a patient with Henoch-Schönlein vasculitis. More research is needed to evaluate the clinical use of FDG-PET/CT in the diagnostic workup of patients with Henoch-Schönlein vasculitis.
Acknowledgements
None. No funding was received by any of the authors.

Authors’ contributions
CFM, EPAHH, and MMI were the treating physicians of the patient; RH, CPB, and LFGe performed and interpreted the FDG-PET/CT images. All authors were involved in drafting the manuscript and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent
Written informed consent was obtained from the patient’s parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Author details
1Department of Pediatrics, Amalia Children’s Hospital, Radboud University Medical Centre, PO Box 91016500 HB Nijmegen, The Netherlands.
2Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, PO Box 91016500 HB Nijmegen, The Netherlands.
3Department of Pediatric Rheumatology, Amalia Children’s Hospital, Radboud University Medical Centre, PO Box 91016500 HB Nijmegen, The Netherlands.
4Department of Internal Medicine, Radboud University Medical Centre, PO Box 91016500 HB Nijmegen, The Netherlands.

Received: 16 December 2015 Accepted: 25 April 2016
Published online: 02 June 2016

References
1. Ozen S, Pistorio A, Iusan SM, Baikakaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69:798–806.
2. McCarthy HJ, Tizard EJ. Clinical practice: diagnosis and management of Henoch-Schönlein purpura. Eur J Pediatr. 2010;169:443–50.
3. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch–Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202.
4. Nielsen HE. Epidemiology of Schönlein-Henoch purpura. Acta Paediatr Scand. 1988;66:125–31.
5. Farley TA, Gillespie S, Rasoulpour M, Tolentino N, Hadler JL, Hurwitz E. Epidemiology of a cluster of Henoch-Schönlein purpura. Am J Dis Child. 1989;143:798–803.
6. Dolezalová P, Teleksová P, Nemcová D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol. 2004;31:2295–9.
7. Tizard EJ, Hamilton-Ayres MJ. Henoch-Schönlein purpura. Arch Dis Child Educ Pract Ed. 2008;93:1–8.
8. Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999;78:395–409.
9. Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in children: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005;35:143–53.
10. Chen Q, Zhu XB, Wang YB, Sun RP, Wei DE. Henoch Schonlein purpura in children: clinical analysis of 120 cases. Afr J Health Sci. 2013;13:94–9.
11. Hammond HM, Bargawi MA. Henoch-Schönlein purpura in children. Influence of age on the incidence of nephritis and arthritis. Saudi Med J. 2008;29:49–52.
12. García-Porrúa C, Calviño MC, Llorca J, Cousello JM, González-Gay MA. Henoch-Schönlein purpura in children and adults: clinical differences in a defined population. Semin Arthritis Rheum. 2002;32:149–56.
13. Fretzayas A, Sionti I, Moustaki M, Papadimitriou A, Nicolaidou P. Henoch-Schönlein purpura: a long-term prospective study in Greek children. J Clin Rheumatol. 2008;14:324–31.
14. Nanke Y, Kotake S, Momohara S, Tateishi M, Yamashita H, Kumatani N. Synovial histology in three Behçet’s disease patients with orthopedic surgery. Clin Exp Rheumatol. 2002;20:535–39.
15. Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence? Clin Rev Allergy Immunol. 2005;29:137–45.
16. Nakazawa J, Watanabe A, Nakajima T, Mishina T, Miyajima M, Higami T. Henoch-Schönlein purpura with lung abscess. Kyobu Geka. 2013;66:886–9.
17. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJG. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med Technol. 2013;41:157–69.
18. Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther. 2014;16:423.
19. Soliman M, Lauer R, Manson D, Yeung R, Doria AS. Imaging of systemic vasculitis in childhood. Pediatr Radiol. 2015;45:1110–25.
20. Zeizer J, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, et al. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol. 2010;73:504–9.
21. Danve A, O’Dell J. The role of 18F fluorodeoxyglucose positron tomography scanning in the diagnosis and management of systemic vasculitis. Int J Rheum Dis. 2015;18:714–24.
22. Nelson DR, Johnson GB, Carin-Ceba R, Specks U. Characterization of F-18 fluorodeoxyglucose PET/CT in granulomatosis with polyangiitis. Sarcoidosis Vasc Diffuse Lung Dis. 2016;32:342–52.